Darovasertib and Crizotinib for HLA-A2-Negative Metastatic Uveal

Darovasertib and Crizotinib for HLA-A2-Negative Metastatic Uveal Melanoma
47%36%25%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 21 • YES 42.3%May 22 • YES 35.9%May 23 • YES 42.3%May 24 • YES 33.9%May 26 • YES 30.2%May 27 • YES 42.0%
IDEAYA Biosciences ($IDYA)
No stock close$29.86$28.99$28.11May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • IDYA $28.32May 19 • IDYA $28.32May 20 • IDYA $29.65May 21 • IDYA $29.54May 22 • IDYA $29.10May 26 • IDYA $29.35May 27 • IDYA $29.28

Will this trial show a positive result on overall survival in Phase 3?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
NO DECISIONPending Review87% confidenceGPT-5.5 (OpenAI)
Question
Will this trial show a positive result on overall survival in Phase 3?
Found
Summary

OptimUM-02 topline was positive for PFS/ORR, but the sponsor explicitly states OS data are not mature and only describes an early OS trend. This is insufficient to classify the Phase 3 OS result as clearly positive.

Sources
Sponsorir.ideayabio.com
IDEAYA and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial OptimUM-02

Sponsor says the trial met primary PFS endpoint and showed ORR benefit; OS data were not mature, with only an early trend toward OS improvement.

Stats
Latest Run
Model
GPT-5.5 (OpenAI)
Runs
2 runs